CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 3.48 USD 9.09% Market Closed
Updated: May 17, 2024

Intrinsic Value

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). [ Read More ]

The intrinsic value of one CVAC stock under the Base Case scenario is hidden USD. Compared to the current market price of 3.48 USD, CureVac NV is hidden .

Key Points:
CVAC Intrinsic Value
HIDDEN
Unlock
Worst Case
Base Case
Best Case

Valuation Backtest
CureVac NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CVAC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
CureVac NV

Provide an overview of the primary business activities
of CureVac NV.

What unique competitive advantages
does CureVac NV hold over its rivals?

What risks and challenges
does CureVac NV face in the near future?

Summarize the latest earnings call
of CureVac NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CureVac NV.

Provide P/S
for CureVac NV.

Provide P/E
for CureVac NV.

Provide P/OCF
for CureVac NV.

Provide P/FCFE
for CureVac NV.

Provide P/B
for CureVac NV.

Provide EV/S
for CureVac NV.

Provide EV/GP
for CureVac NV.

Provide EV/EBITDA
for CureVac NV.

Provide EV/EBIT
for CureVac NV.

Provide EV/OCF
for CureVac NV.

Provide EV/FCFF
for CureVac NV.

Provide EV/IC
for CureVac NV.

Show me price targets
for CureVac NV made by professional analysts.

What are the Revenue projections
for CureVac NV?

How accurate were the past Revenue estimates
for CureVac NV?

What are the Net Income projections
for CureVac NV?

How accurate were the past Net Income estimates
for CureVac NV?

What are the EPS projections
for CureVac NV?

How accurate were the past EPS estimates
for CureVac NV?

What are the EBIT projections
for CureVac NV?

How accurate were the past EBIT estimates
for CureVac NV?

Compare the revenue forecasts
for CureVac NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CureVac NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CureVac NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of CureVac NV compared to its peers.

Compare the P/E ratios
of CureVac NV against its peers.

Discuss the investment returns and shareholder value creation
comparing CureVac NV with its peers.

Analyze the financial leverage
of CureVac NV compared to its main competitors.

Show all profitability ratios
for CureVac NV.

Provide ROE
for CureVac NV.

Provide ROA
for CureVac NV.

Provide ROIC
for CureVac NV.

Provide ROCE
for CureVac NV.

Provide Gross Margin
for CureVac NV.

Provide Operating Margin
for CureVac NV.

Provide Net Margin
for CureVac NV.

Provide FCF Margin
for CureVac NV.

Show all solvency ratios
for CureVac NV.

Provide D/E Ratio
for CureVac NV.

Provide D/A Ratio
for CureVac NV.

Provide Interest Coverage Ratio
for CureVac NV.

Provide Altman Z-Score Ratio
for CureVac NV.

Provide Quick Ratio
for CureVac NV.

Provide Current Ratio
for CureVac NV.

Provide Cash Ratio
for CureVac NV.

What is the historical Revenue growth
over the last 5 years for CureVac NV?

What is the historical Net Income growth
over the last 5 years for CureVac NV?

What is the current Free Cash Flow
of CureVac NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for CureVac NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CureVac NV

Current Assets 478.4m
Cash & Short-Term Investments 405.1m
Receivables 22.3m
Other Current Assets 51m
Non-Current Assets 309.9m
PP&E 278.6m
Intangibles 28.3m
Other Non-Current Assets 2.9m
Current Liabilities 186.4m
Accounts Payable 48m
Other Current Liabilities 138.4m
Non-Current Liabilities 84.9m
Long-Term Debt 36.8m
Other Non-Current Liabilities 48.1m
Efficiency

Earnings Waterfall
CureVac NV

Revenue
53.8m EUR
Cost of Revenue
-116.3m EUR
Gross Profit
-62.5m EUR
Operating Expenses
-207.2m EUR
Operating Income
-269.7m EUR
Other Expenses
9.5m EUR
Net Income
-260.2m EUR

Free Cash Flow Analysis
CureVac NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CVAC Profitability Score
Profitability Due Diligence

CureVac NV's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
ROE is Increasing
Positive 3-Years Revenue Growth
hidden
Profitability
Score

CureVac NV's profitability score is hidden . The higher the profitability score, the more profitable the company is.

CVAC Solvency Score
Solvency Due Diligence

CureVac NV's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
hidden
Solvency
Score

CureVac NV's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CVAC Price Targets Summary
CureVac NV

Wall Street analysts forecast CVAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CVAC is 9.27 USD with a low forecast of 2.63 USD and a high forecast of 18.9 USD.

Lowest
Price Target
2.63 USD
25% Downside
Average
Price Target
9.27 USD
166% Upside
Highest
Price Target
18.9 USD
443% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
CureVac NV

Shareholder Return

CVAC Price
CureVac NV

1M 1M
+35%
6M 6M
-38%
1Y 1Y
-62%
3Y 3Y
-97%
5Y 5Y
-94%
10Y 10Y
-94%
Annual Price Range
3.48
52w Low
2.31
52w High
12.25
Price Metrics
Average Annual Return -29.41%
Standard Deviation of Annual Returns 71.67%
Max Drawdown -98%
Shares Statistics
Market Capitalization 779.5m USD
Shares Outstanding 223 920 000
Percentage of Shares Shorted 10.96%

CVAC Return Decomposition
Main factors of price return

What is price return decomposition?

CVAC News

Other Videos

Last Important Events
CureVac NV

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
CureVac NV

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

CureVac NV Logo
CureVac NV

Country

Germany

Industry

Biotechnology

Market Cap

779.5m USD

Dividend Yield

0%

Description

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

Contact

BADEN-WUERTTEMBERG
Tuebingen
Friedrich-Miescher-Str. 15
+49707198830.0
https://www.curevac.com/en/

IPO

2020-08-14

Employees

500

Officers

MD, CFO & Member of Management Board
Mr. Pierre Kemula B.Sc.
COO, Member of Management Board & MD
Dr. Malte Greune Ph.D.
Senior VP & Area Head of Oncology
Dr. Ulrike Gnad-Vogt M.D., Ph.D.
CEO, MD & Member of Management Board
Dr. Alexander Zehnder M.B.A., M.D.
Chief Development Officer, MD & Member of the Management Board
Dr. Myriam Mendila M.D.
Vice President Corporate Communications & Investor Relations
Dr. Sarah Fakih
Show More
General Counsel
Mr. Marco Rau L.L.M., Ph.D.
Head of Corporate Communications
Mr. Thorsten Schuller
Head of Human Resources
Slavica Stevanovic-Heck
Senior Vice President of Technology
Dr. Patrick Baumhof
Show Less

See Also

Discover More
What is the Intrinsic Value of one CVAC stock?

The intrinsic value of one CVAC stock under the Base Case scenario is hidden USD.

Is CVAC stock undervalued or overvalued?

Compared to the current market price of 3.48 USD, CureVac NV is hidden .